Best Agrolife Ltd. · NSE:BESTAGRO
Best Agrolife — Q2 FY27 Earnings Presentation
19 slides from Best Agrolife's earnings presentation, Nov 1, 2026
Slide 1: Intimation under Regulation 30 - Corporate Presentation
WBest Af,ohrelim,,i CIN : L74l lODL] 992P1C116773 1$November,2O26 To National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block-G, 25th Floor, P.f. Towers, Bandra - Kurla Complex Dalal Street, Mumbai-40000 1 Bandra (E), Mumbai-400051 SCRIP CODE: 539660 SCRIP ID: BESTAGRO Sub: In
Slide 2: Financial Performance Q2 & H1 FY26-27
FINANCIAL PERFORMANCE Q2 & H1 FY26-27
Slide 3: Disclaimer
DISCLAIMER The Presentation is to provide the general background information about the company’s activities as at the date of the presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Table of Contents
TABLE OF CONTENTS This image cannot currently be display ed. Company Snapshot Management’s comment This image cannot currently be display ed. This image cannot currently be display ed. Patent & Latest Launches Registrations & Global This image cannot currently be display ed. presence This image cann
Slide 5: Company Overview
COMPANY OVERVIEW 43 12+ 10,900+ 2 Warehouses Patented Dealers R&D Centers 21 States Products 4 530+ 800+ 4 Manufacturing units Formulations Employees Global presence in 7,000 MTPA Technical Registrations Brazil, China, 35,500 KL Formulation Mauritius, UK *Agropages Top 20 Indian Agrochemical Compani
Slide 6: From MD's Desk
FROM MD’S DESK “Q2FY27 was a challenging quarter for the domestic crop protection industry. Irregular monsoon rainfall delayed and uneven sowing, moisture stress and limited irrigation availability across several agricultural regions affected crop establishment and the timing of crop protection appl
Slide 7: Key Patented Products
KEY PATENTED PRODUCTS P A T E N T P O W E R RONFENTM TRICOLORTM DINOTREXTM NEMAGENTM SHOT DOWNTM Insecticide (SC) Fungicide (SC) Insecticide + Fungicide (WG) Insecticide (SC) Herbicide (ME) Pyriproxyfen - 8% Trifloxystrobin - 10% Pymetrozine - 30% Chlorantraniliprole - 4.5% Haloxyfop-R Methyl - 12.8
Slide 8: Latest Launches: Patented
LATEST LAUNCHES: PATENTED P AT E N T E D I N N O V AT I O N S . P R O V E N P E R F O R M A N C E . FLUZAMTM CUBAX POWER MIDCOTINTM Insecticide + Fungicide (FS) EXTRATM Insecticide + Fungicide (SE) Insecticide (SC) Trifloxystrobin - 4% lsoprothiolane - 15% Fluxapyroxad - 6.66% Spiromesifen - 15% Tri
Slide 9: Latest Launches: Bio-Fertilizers / Plant Growth Regulators
LATEST LAUNCHES: BIO-FERTILIZERS / PLANT GROWTH REGULATORS N AT U R E ' S I N T E L L I G E N C E . E N H A N C E D C R O P P E R F O R M A N C E . PUNCTUALTM SPRINKTM RICHGROW GOLDTM TORNET TM EMPROLETM It is an organic potassium It is a highly concentrated It harnesses the natural power of It is a
Slide 10: Patent & Registrations
PATENT & REGISTRATIONS Domestic Registrations Obtained the patent grant for the combination of Fluxametamide + Abamectin + Trifloxystrobin, to support our broader focus on developing differentiated products. Secured 13 New Central Insecticides Board (CIB) registrations this quarter in various catego
Slide 11: Highlights Q2 FY27
HIGHLIGHTS Q2 FY27 • Revenue for Q2 FY27 stood at ₹407 crore, compared to ₹517 crore in Value (INR Cr) Q2 FY27 Q2 FY26 % Y-o-Y Q2 FY26, reflecting a 21% YoY decline, due to erratic rainfall, delayed sowing and lower crop protection demand . Revenue from 407 517 (21)% Operations • Gross Margin improv
Slide 12: Financial Highlights Q2 FY27
FINANCIAL HIGHLIGHTS Q2 FY27 Revenue from operations EBITDA* Branded v/s Institutional Sales -21% 30% (₹ Crore) 19% 31% (₹ Crore) 517 407 78 101 69% 81% Q2 FY26 Q2 FY27 Q2 FY26 Q2 FY27 Q2 FY26 Q2 FY27 Branded Institutional Sales PAT EPS Contribution of Patented products in Branded Sales 48% 41% (₹ C
Slide 13: Highlights H1 FY27
HIGHLIGHTS H1 FY27 Value (INR Cr) H1 FY27 H1 FY26 % Y-o-Y • Revenue for H1 FY27 stood at ₹803 crore, compared to ₹898 crore in H1 FY26, reflecting a 11% YoY decline, due to erratic rainfall, delayed sowing Revenue from and lower crop protection demand . 803 898 (11)% Operations • Gross Margin improv
Slide 14: Financial Highlights H1 FY27
FINANCIAL HIGHLIGHTS H1 FY27 Revenue from operations EBITDA* Branded v/s Institutional Sales -11% 45% (₹ Crore) 33% 29% (₹ Crore) 898 803 123 178 67% 71% H1 FY26 H1 FY27 H1 FY26 H1 FY27 H1 FY26 H1 FY27 Branded Institutional Sales PAT EPS Contribution of Patented products in Branded Sales 67% 67% (₹
Slide 15: Consolidated Balance Sheet
CONSOLIDATED BALANCE SHEET Value (INR Cr) As on Sept 30, 2026 As on Sept 30, 2025 As on Mar 31, 2026 Equity And Liabilities Share Holders Fund 864 809 769 Non-current Liabilities • Long Term Borrowings 73 12 27 • Other Financial Liabilities 38 33 32 Total Non-current Liabilities 111 45 59 Current Li
Slide 16: Key Ratios
KEY RATIOS Improvement in key financial ratios reflects a stronger balance sheet, reduced leverage, enhanced liquidity, and improved capital efficiency. Debt to Equity Net Debt to Equity 0.90 0.97 0.62 0.56 0.48 0.53 0.44 0.43 FY24 FY25 FY26 H1 FY27 FY24 FY25 FY26 H1 FY27 Current Ratio ROCE 1.53 1.6
Slide 17: Working Capital Movement
WORKING CAPITAL MOVEMENT Improvement across key working capital metrics reflects enhanced operational efficiency, better cash flow management, and a stronger financial position. Receivable Days Inventory Days 151 124 292 272 FY26 H1 FY27 FY26 H1 FY27 Cash Conversion Days Working Capital Days 267 255
Slide 18: Experienced Management Team
EXPERIENCED MANAGEMENT TEAM Mr. Vimal Kumar Mr. P. N. Karlekar Mr. N Surendra Sai Mr. Sanjeev Bajaj Managing Director Managing Director (BCS) Executive Director Chief Financial Officer A t rue visionary and a pa ssionat e A chemical Engineer from UDCT- one of A pass ionate t echnolo gist and Mr. San
Slide 19: Thank You
THANK YOU !!! Contact Us: [email protected] (Investor Relations) DISCLAIMER This presentation includes certain forward looking statements and information including statements concerning the outlook for business. The statements are based on certain expectations, assumptions, anticipated development